Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib

Published:2009-10 Issue:1 Volume:66 Page:114-119
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Ma Fei,Sun Tong,Shi Yuankai,Yu Dianke,Tan Wen,Yang Ming,Wu Chen,Chu Datong,Sun Yan,Xu Binghe,Lin Dongxin

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference40 articles.

1. Updates in non-small cell lung cancer;Walker;Clin J Oncol Nurs,2008

2. Multidisciplinary management of lung cancer;Spira;N Engl J Med,2004

3. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer;Schiller;N Engl J Med,2002

4. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group;Fossella;J Clin Oncol,2003

5. Multi-institutional randomized phase II trial of Gefitinib for previously treated patients with advanced non-small-cell lung cancer;Fukuoka;J Clin Oncol,2003

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analyses of P16INK4a gene promoter methylation relative to molecular, demographic and clinical parameters characteristics in non-small cell lung cancer patients: A pilot study;Molecular Biology Reports;2022-11-15

2. Two missense variants of the epidermal growth factor receptor gene are associated with non small cell lung carcinoma in the subjects from Iraq;Molecular Biology Reports;2022-09-28

3. Evaluation of Clinical and Genetic Determinants of Treatment OutCome In EGFR Mutation Positive Advanced Lung Adenocarcinoma;Dose-Response;2022-07

4. Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer;Drug Resistance Updates;2022-05

5. SNPs and Personalized Medicine: Scrutinizing Pathogenic Synonymous Mutations for Precision Oncology;Single Nucleotide Polymorphisms;2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3